Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹2934 Cr.
Stock P/E
16.9
P/B
1.8
Current Price
₹262
Book Value
₹ 148.4
Face Value
2
52W High
₹419.8
52W Low
₹ 251.9
Dividend Yield
2.04%

Advanced Enzyme Tech Overview

Business

Advanced Enzyme Technologies Ltd. (ADVENZYMES) is a research and development-driven company primarily engaged in the manufacturing and marketing of enzymes and enzyme blends. The company develops, manufactures, and supplies over 400 proprietary enzyme products across 68 countries. Its core business model involves leveraging its expertise in microbial fermentation and enzyme technology to produce specialty enzymes used in various industries. The company makes money by selling these enzyme products to B2B customers in sectors like human nutrition (digestive aids, probiotics, nutraceuticals), animal nutrition (feed enzymes), industrial applications (textile, food & beverage processing, biofuels), and bio-processing.

Revenue Mix

The company broadly categorizes its products into:

Human Nutrition: This segment focuses on enzymes for digestive health, immunity, anti-inflammatory applications, and probiotics for supplements, functional foods, and pharmaceutical applications. This is typically the largest revenue contributor.

Animal Nutrition: Enzymes used in animal feed to improve digestion, nutrient absorption, and overall animal health.

Bio-processing & Industrial Applications: Enzymes tailored for use in various industrial processes such as food & beverage processing (dairy, baking, brewing), textile processing, waste management, and biofuels.

While specific contribution percentages fluctuate, Human Nutrition generally constitutes the largest portion of revenue, followed by Animal Nutrition and Industrial applications.

Industry

Advanced Enzyme Technologies operates in the global enzyme industry, which is a niche but growing part of the broader biotechnology and specialty chemicals sector. The industry is characterized by significant R&D investment, technical expertise, and stringent quality standards. Globally, it competes with large multinational players like Novozymes, IFF (DuPont Nutrition & Biosciences), DSM, and BASF, as well as several smaller, specialized enzyme manufacturers. ADVENZYMES is one of India's largest enzyme manufacturers and is positioned as a leading player in specific enzyme categories globally, particularly in digestive enzymes and certain nutraceutical formulations. Its strength lies in its extensive product portfolio, proprietary enzyme strains, and ability to customize solutions.

MOAT

R&D and Proprietary Technology: The company has a strong focus on R&D, leading to the development of proprietary enzyme strains and manufacturing processes. This creates barriers to entry for competitors.

Comprehensive Product Portfolio: A wide range of 400+ enzyme products caters to diverse applications, allowing for cross-selling and diversified revenue streams.

Quality & Regulatory Compliance: Adherence to global quality standards (e.g., USFDA, FSSC 22000, ISO 22000, HALAL, KOSHER) ensures product acceptance in regulated markets and builds customer trust.

Customer Stickiness: For specific industrial applications, switching enzyme suppliers can be costly and time-consuming due to the need for re-validation and process adjustments.

Manufacturing Scale and Cost Efficiency: Operating large-scale fermentation facilities allows for economies of scale, potentially leading to competitive pricing.

Growth Drivers

Rising Demand in Human Nutrition: Growing consumer awareness about health, wellness, digestive health, and immunity drives demand for nutraceuticals, probiotics, and enzyme supplements.

Growth in Animal Feed Industry: Increasing global meat and dairy consumption fuels demand for feed enzymes to improve feed conversion ratios and reduce antibiotic usage.

Shift Towards Bio-based Solutions: A global trend towards replacing chemical processes with eco-friendly enzyme-based solutions across various industries (food, textiles, biofuels).

Geographic Expansion: Penetration into new international markets and strengthening presence in existing ones, especially in regions with growing middle-class populations.

New Product Development: Continuous innovation and launch of novel enzymes for new applications or improved efficacy.

Risks

Raw Material Price Volatility: Key raw materials for fermentation (e.g., corn, soy, molasses) are agricultural commodities, subject to price fluctuations.

Intense Competition & Pricing Pressure: The presence of large global players and several regional competitors can lead to pricing pressure and impact profitability.

Regulatory Changes: Stricter regulations in the food, pharmaceutical, and animal feed industries in various countries could impact product approvals and market access.

Technological Obsolescence: Rapid advancements in biotechnology mean that existing enzyme products or production methods could become obsolete if competitors introduce superior alternatives.

Dependency on End-Use Industries: Performance is linked to the growth and health of the nutraceutical, animal feed, and industrial sectors, which can be cyclical.

Foreign Exchange Fluctuations: Significant international sales expose the company to currency exchange rate risks.

Management & Ownership

Advanced Enzyme Technologies is a promoter-led company with Mr. V. C. Rathi (Chairman & Managing Director) and Mr. C. L. Rathi (Jt. Managing Director) being key figures from the promoter group. The management team generally possesses long-standing experience in the enzyme and biotechnology sectors. The ownership structure typically includes a significant promoter holding, institutional investors (both domestic and foreign), and public shareholders. The promoter's deep industry knowledge and strategic vision are often cited as strengths.

Outlook

Advanced Enzyme Technologies is well-positioned to capitalize on the secular growth trends in the global enzyme market, driven by increasing demand for health and wellness products, sustainable industrial solutions, and efficient animal nutrition. Its strong R&D capabilities, diverse product portfolio, and established global presence provide a solid foundation for future growth. However, the company operates in a competitive and technically demanding industry. Success will depend on its ability to continuously innovate, manage raw material costs, navigate complex regulatory landscapes, and effectively compete with both global giants and specialized players. While the underlying demand drivers are favorable, potential challenges from intense competition, R&D success rates, and macroeconomic factors remain important considerations.

Advanced Enzyme Tech Share Price

Live · BSE / NSE · Inception: 1989
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Advanced Enzyme Tech Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 158 155 146 169 167 186 185 172 203 190
Other Income 9 7 10 8 9 9 10 8 7 13
Total Income 167 162 156 177 176 195 195 180 211 203
Total Expenditure 102 103 104 114 122 129 124 123 140 139
Operating Profit 65 58 52 63 54 65 70 58 70 64
Interest 1 1 1 1 1 1 1 1 1 1
Depreciation 9 9 9 9 10 10 10 10 10 10
Exceptional Income / Expenses -15 0 0 0 0 0 0 11 0 0
Profit Before Tax 40 49 42 53 43 55 60 58 60 54
Provision for Tax 10 14 9 14 17 14 15 15 15 15
Profit After Tax 30 35 33 39 27 40 45 43 45 39
Adjustments -2 -1 -1 -1 -0 -1 -1 -1 -2 -1
Profit After Adjustments 28 34 33 38 26 40 43 43 43 37
Adjusted Earnings Per Share 2.5 3.1 2.9 3.4 2.4 3.6 3.9 3.8 3.8 3.3

Advanced Enzyme Tech Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 294 329 391 420 444 502 529 541 624 637 746 750
Other Income 1 3 3 6 6 9 6 25 37 33 36 38
Total Income 295 332 394 425 450 511 536 566 661 670 782 789
Total Expenditure 156 178 227 237 241 269 327 383 419 441 516 526
Operating Profit 139 154 166 188 209 241 209 183 242 229 265 262
Interest 8 4 9 5 4 3 3 3 4 5 4 4
Depreciation 9 13 18 21 26 29 35 35 35 37 40 40
Exceptional Income / Expenses -4 0 0 0 0 0 0 -4 -15 0 11 11
Profit Before Tax 118 137 139 162 179 210 171 140 188 187 233 232
Provision for Tax 41 44 45 46 46 59 47 37 51 53 59 60
Profit After Tax 77 93 94 116 133 151 124 104 137 134 174 172
Adjustments -1 -1 -3 -5 -4 -5 -4 2 -4 -3 -5 -5
Profit After Adjustments 76 92 90 111 129 146 120 106 133 131 169 166
Adjusted Earnings Per Share 7 8.2 8.1 9.9 11.6 13.1 10.7 9.4 11.9 11.7 15.1 14.8

Advanced Enzyme Tech Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 278 464 559 679 840 971 1089 1235 1324 1421 1632
Minority's Interest 5 21 23 26 28 62 52 49 47 48 51
Borrowings 39 19 20 7 4 10 8 8 7 9 8
Other Non-Current Liabilities 17 13 23 23 35 39 51 41 37 37 36
Total Current Liabilities 111 62 99 65 60 68 60 78 106 96 107
Total Liabilities 450 583 727 805 971 1149 1260 1411 1521 1611 1834
Fixed Assets 285 421 491 495 563 604 619 649 650 679 692
Other Non-Current Assets 25 18 21 23 28 29 37 39 62 53 98
Total Current Assets 140 138 211 282 376 516 604 722 810 880 1044
Total Assets 450 583 727 805 971 1149 1260 1411 1521 1611 1834

Advanced Enzyme Tech Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 4 25 8 61 23 83 192 267 96 114 94
Cash Flow from Operating Activities 93 107 116 129 141 163 122 140 141 142 157
Cash Flow from Investing Activities -5 -60 -78 -125 -44 -26 -4 -298 -65 -89 -74
Cash Flow from Financing Activities -63 -65 -2 -43 -39 -26 -49 -26 -59 -73 -70
Net Cash Inflow / Outflow 26 -18 36 -39 58 111 70 -184 17 -19 12
Closing Cash & Cash Equivalent 25 8 61 23 83 192 267 96 114 94 109

Advanced Enzyme Tech Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 6.97 8.2 8.08 9.95 11.58 13.06 10.7 9.45 11.92 11.72 15.07
CEPS(Rs) 7.85 9.47 10.02 12.27 14.22 16.11 14.2 12.42 15.4 15.24 19.09
DPS(Rs) 0.2 0.4 0.5 0.6 0.6 0.9 1 1 5.1 5.2 5.35
Book NAV/Share(Rs) 25.55 41.54 49.85 60.49 74.86 86.67 97.31 110.45 118.14 126.56 144.99
Core EBITDA Margin(%) 45.18 44.14 41.34 43.5 45.74 46.74 38.19 29.09 32.87 30.7 30.69
EBIT Margin(%) 41.4 41.24 37.42 39.83 41.26 42.75 32.8 26.57 30.73 30.15 31.62
Pre Tax Margin(%) 38.82 39.95 35.13 38.59 40.34 42.23 32.25 25.93 30.07 29.42 31.12
PAT Margin (%) 25.21 27.09 23.65 27.62 29.96 30.41 23.34 19.18 21.92 21.04 23.24
Cash Profit Margin (%) 28.07 30.81 28.27 32.65 35.76 36.18 29.93 25.65 27.57 26.77 28.6
ROA(%) 17.81 18 14.28 15.13 14.98 14.27 10.28 7.78 9.34 8.55 10.08
ROE(%) 31.32 25.06 18.34 18.82 17.61 16.77 12.04 8.94 10.72 9.79 11.43
ROCE(%) 35.68 31.53 25.88 24.96 23.21 22.93 16.66 12.26 14.78 13.76 15.27
Receivable days 47.26 48.73 50.01 51.02 54.83 59.04 60.03 63.55 58.11 61.31 63.61
Inventory Days 67.81 68.6 66.45 66.31 64.49 63.79 73.9 82.55 79.59 87.61 81.73
Payable days 68.75 57.95 63.8 64.17 43.59 45.81 55.08 58.32 50.47 42.35 56.22
PER(x) 0 50.25 26.38 18.39 12.36 26.4 26.37 24.52 29.15 23.8 16.94
Price/Book(x) 0 9.92 4.27 3.02 1.91 3.98 2.9 2.1 2.94 2.2 1.76
Dividend Yield(%) 0 0.1 0.23 0.33 0.42 0.26 0.35 0.43 1.47 1.86 2.09
EV/Net Sales(x) 0.33 14.12 6.1 4.89 3.47 7.32 5.46 4.59 6.07 4.76 3.71
EV/Core EBITDA(x) 0.7 30.12 14.33 10.91 7.37 15.22 13.83 13.56 15.62 13.28 10.43
Net Sales Growth(%) 31.67 11.99 18.85 7.31 5.81 13.03 5.49 2.13 15.4 2.09 17.09
EBIT Growth(%) 49.93 12.26 4.63 12.93 9.61 16.08 -18.19 -17.32 33.42 0.03 23.06
PAT Growth(%) 48.12 21.1 0.66 23.89 14.79 13.71 -18.17 -16.1 31.85 -2.17 29.58
EPS Growth(%) 48.78 17.64 -1.5 23.16 16.39 12.82 -18.11 -11.68 26.19 -1.69 28.63
Debt/Equity(x) 0.36 0.12 0.12 0.05 0.03 0.02 0.01 0.01 0.02 0.02 0.01
Current Ratio(x) 1.26 2.24 2.13 4.33 6.31 7.64 10 9.31 7.61 9.14 9.78
Quick Ratio(x) 0.72 1.13 1.37 3.15 4.96 6.25 8 7.71 6.22 7.51 8.12
Interest Cover(x) 16.04 31.91 16.34 32.13 44.94 82.76 58.89 41.36 46.58 41.44 63.28
Total Debt/Mcap(x) 0 0.01 0.03 0.02 0.02 0 0 0.01 0.01 0.01 0.01

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +17% +11% +8% +10%
Operating Profit CAGR +16% +13% +2% +7%
PAT CAGR +30% +19% +3% +8%
Share Price CAGR -16% -7% -8% -5%
ROE Average +11% +11% +11% +16%
ROCE Average +15% +15% +15% +22%

Advanced Enzyme Tech Shareholding Pattern

Latest · Sep 2026
100% held
Promoters 43.56 %
FII 26.65 %
DII (MF + Insurance) 1.89 %
Public (retail) 27.9 %
# Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Promoter 43.0242.9542.9343.0843.0843.0743.0443.2643.2443.56
FII 12.0312.6312.5811.923.4625.4125.8625.4926.7126.65
DII 8.088.028.178.198.456.415.515.414.781.89
Public 36.8836.4136.3236.8325.0225.125.625.8425.2727.9
Others 0000000000
Total 100100100100100100100100100100

Advanced Enzyme Tech Peer Comparison

Pharmaceuticals & Drugs Edit Columns

Advanced Enzyme Tech Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Advanced Enzyme Tech Pros & Cons

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 43.56%.
  • Company has a low return on equity of 11% over the last 3 years.
  • Debtor days have increased from 42.35 to 56.22days.
  • The company has delivered a poor profit growth of 2% over past five years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp